29 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
Novartis Pharma
Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors.
Novartis Institutes For Biomedical Research
Discovery of a new isomannide-based peptidomimetic synthetized by Ugi multicomponent reaction as human tissue kallikrein 1 inhibitor.
Universidade Federal Fluminense
Isocoumarins, miraculous natural products blessed with diverse pharmacological activities.
Quaid-I-Azam University
The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins.
Campus
Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library.
Queensland University Of Technology
Pyrido-imidazodiazepinones as a new class of reversible inhibitors of human kallikrein 7.
University Of Montpellier
Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7.
Universidade Federal Do Abc
Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.
Universit£
1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases.
Universit£
Isomannide derivatives as new class of inhibitors for human kallikrein 7.
Universidade Federal Do Tri£Ngulo Mineiro
Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7.
Universidade Federal Do Tri£Ngulo Mineiro
Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.
Glaxosmithkline R&D
Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.
Glaxosmithkline
Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.
Glaxosmithkline R&D
Binding Loop Substitutions in the Cyclic Peptide SFTI-1 Generate Potent and Selective Chymase Inhibitors.
The University Of Queensland
Discovery and structure-activity relationship of imidazolinylindole derivatives as kallikrein 7 inhibitors.
Asubio Pharma
Amino Acid Scanning at P5' within the Bowman-Birk Inhibitory Loop Reveals Specificity Trends for Diverse Serine Proteases.
The University Of Queensland
Potent, Selective, and Cell-Penetrating Inhibitors of Kallikrein-Related Peptidase 4 Based on the Cyclic Peptide MCoTI-II.
The University Of Queensland
3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7.
Universidade Federal Fluminense
Structure-based drug design of 1,3,6-trisubstituted 1,4-diazepan-7-ones as selective human kallikrein 7 inhibitors.
Asubio Pharma
Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.
German Cancer Research Center (Dkfz)
Discovery and structure-activity relationship study of 1,3,6-trisubstituted 1,4-diazepane-7-ones as novel human kallikrein 7 inhibitors.
Asubio Pharma
Discovery, Synthesis, Pharmacological Profiling, and Biological Characterization of Brintonamides A-E, Novel Dual Protease and GPCR Modulators from a Marine Cyanobacterium.
University Of Florida
Structure-based drug design to overcome species differences in kallikrein 7 inhibition of 1,3,6-trisubstituted 1,4-diazepan-7-ones.
Asubio Pharma
Design of Potent and Selective Cathepsin G Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold.
The University Of Queensland
Transition state analogues of Plasmodium falciparum and human orotate phosphoribosyltransferases.
Albert Einstein College Of Medicine
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance.
University Of Cambridge